CDK4/6 blockade in breast cancer: current experience and future perspectives

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is characterized by uncontrolled cell growth, often driven by dysregulated cell cycle progression involving cyclin-dependent kinases (CDKs).
• Early CDK inhibitors lacked efficacy and showed significant toxicity.
• Selective CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) have emerged as effective treatments for specific breast cancer types.

Purpose of the Study:

• To review the approval and application of selective CDK4/6 inhibitors in advanced hormone receptor-positive, HER2-negative breast cancer.
• To present data on predictive biomarkers for CDK4/6 inhibitor efficacy.
• To discuss preclinical and early clinical evidence for CDK4/6 inhibition in other breast cancer subtypes.

Main Methods:

• Literature review of clinical trials and preclinical studies on CDK4/6 inhibitors in breast cancer.
• Analysis of data on approved indications and emerging therapeutic strategies.
• Synthesis of expert opinion on future research directions.

Main Results:

• CDK4/6 inhibitors are approved for advanced hormone receptor-positive, HER2-negative breast cancer.
• Evidence suggests potential utility in other breast cancer subtypes.
• Biomarker research is ongoing to predict treatment response.

Conclusions:

• Selective CDK4/6 inhibitors represent a significant advancement in breast cancer therapy.
• Future research will focus on optimizing treatment sequencing, exploring early-stage disease applications, and identifying predictive biomarkers.
• Combination therapies and novel applications in different breast cancer subtypes are promising avenues.